{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:28:10Z","timestamp":1793381290015,"version":"4.5.0"},"reference-count":105,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The most common liver diseases are fibrosis, alcoholic liver disease, nonalcoholic\nfatty disease, viral hepatitis, and hepatocellular carcinoma. These liver diseases account\nfor approximately 2 million deaths per year worldwide, with cirrhosis accounting for 2.1% of the\nworldwide burden. The most widely used liver function tests for diagnosis are alanine transaminase,\naspartate transaminase, serum proteins, serum albumin, and serum globulins, whereas antivirals\nand corticosteroids have been proven to be useful for the treatment of liver diseases. A major\ndisadvantage of these diagnostic measures is the lack of specificity to a particular tissue or cell\ntype, as these enzymes are common to one or more tissues. The major adverse effect of current\ntreatment methods is drug resistance. To overcome these issues, interleukins have been investigated.\nThe balance of these interleukins determines the outcome of an immune response. Interleukins\nare considered interesting therapeutic targets for the treatment of liver diseases. In this review, we\nsummarize the current state of knowledge regarding interleukins in the diagnosis, treatment, and\npathogenesis of different acute and chronic liver diseases<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To understand the role of interleukins in the assessment and treatment of different types\nof liver diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, Science Direct, and NCBI with the following\nkeywords: Interleukins, Acute Liver Failure, Alcoholic Liver Disease, Non-Alcoholic Fatty\nLiver Disease, Liver Fibrosis, Hepatocellular Carcinoma, Inflammation, Liver injury, Hepatoprotective\neffect. Clinical trial data on these interleukins have been searched on Clinicaltrials.gov.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Existing literature and preclinical and clinical trial data demonstrate that interleukins play\na crucial role in the pathogenesis of liver diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings indicate that IL-1, IL-6, IL-10, IL-17, IL-22, IL-35, and IL-37 are involved\nin the progression and control of various liver conditions via the regulation of cell signaling\npathways. However, further investigation on the involvement of these interleukins is necessary for\ntheir use as a targeted therapy in liver diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1871530321666211124102837","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T23:16:56Z","timestamp":1637795816000},"page":"371-382","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emerging Role of Interleukins for the Assessment and Treatment of Liver\nDiseases"],"prefix":"10.2174","volume":"22","author":[{"given":"Aaliya L.","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Pharmacology, SVKM\\'S Dr. Bhanuben Nanavati College of Pharmacy, Mithibai Campus, Vile Parle\n(W), Mumbai-400056, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-8568","authenticated-orcid":true,"given":"Namrata P.","family":"Nailwal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SVKM\\'S Dr. Bhanuben Nanavati College of Pharmacy, Mithibai Campus, Vile Parle\n(W), Mumbai-400056, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-0705","authenticated-orcid":true,"given":"Gaurav M.","family":"Doshi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SVKM\\'S Dr. Bhanuben Nanavati College of Pharmacy, Mithibai Campus, Vile Parle\n(W), Mumbai-400056, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","author":"Moore K.L.","year":"2014","unstructured":"Moore K.L.; Dalley A.F.; Agur A.M.R.; Chapter 2: Abdomen. Moore Clinically Oriented Anatomy 2014","journal-title":"Moore Clinically Oriented Anatomy"},{"key":"ref=2","author":"Guyton A.C.","year":"2014","unstructured":"Guyton A.C.; Hall J.B.B.;  Guyton and Hall Textbook of Medical Physiology 2014","journal-title":"Guyton and Hall Textbook of Medical Physiology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","volume":"13","author":"Heymann F.","year":"2016","unstructured":"Heymann F.; Tacke F.; Immunology in the liver from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016,13(2),88-110","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3389\/fimmu.2018.01155","volume":"9","author":"Caparr\u00f3s E.","year":"2018","unstructured":"Caparr\u00f3s E.; Franc\u00e9s R.; The interleukin-20 cytokine family in liver disease. Front Immunol 2018,9,1155","journal-title":"Front Immunol"},{"key":"ref=5","first-page":"1392","author":"Odze R.D.","year":"2009","unstructured":"Odze R.D.; Goldblum J.R.;  Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas 2009,1392","journal-title":"Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cld.562","volume":"8","author":"Kasarala G.","year":"2016","unstructured":"Kasarala G.; Tillmann H.L.; Standard liver tests. Clin Liver Dis 2016,8(1),13-18","journal-title":"Clin Liver Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","volume":"23","author":"Singh S.","year":"2017","unstructured":"Singh S.; Osna N.A.; Kharbanda K.K.; Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017,23(36),6549-6570","journal-title":"World J Gastroenterol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1745-6215-14-262","volume":"14","author":"Forrest E.","year":"2013","unstructured":"Forrest E.; Mellor J.; Stanton L.; Bowers M.; Ryder P.; Austin A.; Day C.; Gleeson D.; O\u2019Grady J.; Masson S.; McCune A.; Patch D.; Richardson P.; Roderick P.; Ryder S.; Wright M.; Thursz M.; Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials 2013,14,262","journal-title":"Trials"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4254\/wjh.v3.i8.205","volume":"3","author":"Singal A.K.","year":"2011","unstructured":"Singal A.K.; Walia I.; Singal A.; Soloway R.D.; Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: Current status. World J Hepatol 2011,3(8),205-210","journal-title":"World J Hepatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jhep.2005.05.037","volume":"43","author":"Fung S.K.","year":"2005","unstructured":"Fung S.K.; Andreone P.; Han S.H.; Rajender Reddy K.; Regev A.; Keeffe E.B.; Hussain M.; Cursaro C.; Richtmyer P.; Marrero J.A.; Lok A.S.; Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005,43(6),937-943","journal-title":"J Hepatol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","volume":"127","author":"Akdis M.","year":"2011","unstructured":"Akdis M.; Burgler S.; Crameri R.; Eiwegger T.; Fujita H.; Gomez E.; Interleukins, from 1 to 37, and interferon-&#x3B3;: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011,127,701-721","journal-title":"J Allergy Clin Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-804214-4.00003-8","author":"Mousa H.S.","year":"2017","unstructured":"Mousa H.S.; Bernuzzi F.; Invernizzi P.; Cytokines in the Liver: Cytokine Mechanisms in Liver Health and Disease.  Cytokine Effector Functions in Tissues 2017,75-96","journal-title":"Cytokine Effector Functions in Tissues"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/07853890500317414","volume":"37","author":"Odeh M.","year":"2005","unstructured":"Odeh M.; Sabo E.; Srugo I.; Oliven A.; Relationship between tumor necrosis factor-alpha and ammonia in patients with hepatic encephalopathy due to chronic liver failure. Ann Med 2005,37(8),603-612","journal-title":"Ann Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3748\/wjg.v13.i3.421","volume":"13","author":"Elsing C.","year":"2007","unstructured":"Elsing C.; Harenberg S.; Stremmel W.; Herrmann T.; Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients. World J Gastroenterol 2007,13(3),421-425","journal-title":"World J Gastroenterol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000232940","volume":"28","author":"Liu Q.","year":"2009","unstructured":"Liu Q.; Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif 2009,28(4),331-341","journal-title":"Blood Purif"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/s-2003-42639","volume":"23","author":"Riordan SM.","year":"2003","unstructured":"Riordan SM.; Williams R.; Mechanisms of hepatocyte injury, multiorgan failure, and prognostic criteria in acute liver failure. InSeminars in liver disease 2003,23,203-216","journal-title":"InSeminars in liver disease"},{"key":"ref=17","first-page":"377","volume":"13","author":"Luedde T.","year":"2002","unstructured":"Luedde T.; Liedtke C.; Manns M.P.; Trautwein C.; Losing balance: cytokine signaling and cell death in the context of hepatocyte injury and hepatic failure. Eur Cytokine Netw 2002,13(4),377-383","journal-title":"Eur Cytokine Netw"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"25369","DOI":"10.1016\/S0021-9258(18)47258-4","volume":"269","author":"Reddy S.A.","year":"1994","unstructured":"Reddy S.A.; Chaturvedi M.M.; Darnay B.G.; Chan H.; Higuchi M.; Aggarwal B.B.; Reconstitution of nuclear factor kappa B activation induced by tumor necrosis factor requires membrane-associated components. Comparison with pathway activated by ceramide. J Biol Chem 1994,269(41),25369-25372","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1203\/00006450-200212000-00018","volume":"52","author":"Doughty L.","year":"2002","unstructured":"Doughty L.; Clark R.S.; Kaplan S.S.; Sasser H.; Carcillo J.; sFas and sFas ligand and pediatric sepsis-induced multiple organ failure syndrome. Pediatr Res 2002,52(6),922-927","journal-title":"Pediatr Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jhep.2014.12.027","volume":"62","author":"Cui K.","year":"2015","unstructured":"Cui K.; Yan G.; Xu C.; Chen Y.; Wang J.; Zhou R.; Bai L.; Lian Z.; Wei H.; Sun R.; Tian Z.; Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1\u03b2 in mice. J Hepatol 2015,62(6),1311-1318","journal-title":"J Hepatol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0300-483X(95)03128-3","volume":"105","author":"Kamm\u00fcller M.E.","year":"1995","unstructured":"Kamm\u00fcller M.E.; Recombinant human interleukin-6: safety issues of a pleiotropic growth factor. Toxicology 1995,105(1),91-107","journal-title":"Toxicology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0168-8278(00)80418-3","volume":"32","author":"Lok A.S.F.","year":"2000","unstructured":"Lok A.S.F.; Hepatitis B infection: pathogenesis and management. J Hepatol 2000,32(1)(Suppl.),89-97","journal-title":"J Hepatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/hep.28456","volume":"64","author":"Tilg H.","year":"2016","unstructured":"Tilg H.; Moschen A.R.; Szabo G.; Interleukin-1 and inflammasomes in alcoholic liver disease\/acute alcoholic hepatitis and nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Hepatology 2016,64(3),955-965","journal-title":"Hepatology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/jcm8020179","volume":"8","author":"Kuna L.","year":"2019","unstructured":"Kuna L.; Jakab J.; Smolic R.; Raguz-Lucic N.; Vcev A.; Smolic M.; Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. J Clin Med 2019,8(2),179","journal-title":"J Clin Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1113\/expphysiol.2012.068338","volume":"98","author":"Bracey N.A.","year":"2013","unstructured":"Bracey N.A.; Beck P.L.; Muruve D.A.; Hirota S.A.; Guo J.; Jabagi H.; Wright J.R.; Macdonald J.A.; Lees-Miller J.P.; Roach D.; Semeniuk L.M.; Duff H.J.; The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1\u03b2. Exp Physiol 2013,98(2),462-472","journal-title":"Exp Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","volume":"3","author":"Lee S.","year":"2011","unstructured":"Lee S.; Margolin K.; Cytokines in cancer immunotherapy. Cancers (Basel) 2011,3(4),3856-3893","journal-title":"Cancers (Basel)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/JAA.S52387","volume":"7","author":"Vatrella A.","year":"2014","unstructured":"Vatrella A.; Fabozzi I.; Calabrese C.; Maselli R.; Pelaia G.; Dupilumab: a novel treatment for asthma. J Asthma Allergy 2014,7,123-130","journal-title":"J Asthma Allergy"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/TCRM.S3470","volume":"4","author":"Hennigan S.","year":"2008","unstructured":"Hennigan S.; Kavanaugh A.; Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2008,4(4),767-775","journal-title":"Ther Clin Risk Manag"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"205873921984340","DOI":"10.1177\/2058739219843405","volume":"17","author":"Meng D.","year":"2019","unstructured":"Meng D.; Liang L.; Guo X.; Serum interleukin-10 level in patients with inflammatory bowel disease: A meta-analysis. Eur J Inflamm 2019,17,205873921984340","journal-title":"Eur J Inflamm"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.intimp.2007.12.004","volume":"8","author":"Vugmeyster Y.","year":"2008","unstructured":"Vugmeyster Y.; Szklut P.; Tchistiakova L.; Abraham W.; Kasaian M.; Xu X.; Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008,8(3),477-483","journal-title":"Int Immunopharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jcrc.2017.01.003","volume":"39","author":"Cardoso F.S.","year":"2017","unstructured":"Cardoso F.S.; Marcelino P.; Bagulho L.; Karvellas C.J.; Acute liver failure: An up-to-date approach. J Crit Care 2017,39,25-30","journal-title":"J Crit Care"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1055\/s-0038-1673372","volume":"39","author":"Rajaram P.","year":"2018","unstructured":"Rajaram P.; Subramanian R.; Acute Liver Failure. Semin Respir Crit Care Med 2018,39(5),513-522","journal-title":"Semin Respir Crit Care Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/jhep.2000.17687","volume":"32","author":"Rolando N.","year":"2000","unstructured":"Rolando N.; Wade J.; Davalos M.; Wendon J.; Philpott-Howard J.; Williams R.; The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000,32(4 Pt 1),734-739","journal-title":"Hepatology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1471-4906(01)02034-8","volume":"22","author":"Dunn E.","year":"2001","unstructured":"Dunn E.; Sims J.E.; Nicklin M.J.H.; O\u2019Neill L.A.J.; Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol 2001,22(10),533-536","journal-title":"Trends Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"Lamkanfi M.","year":"2014","unstructured":"Lamkanfi M.; Dixit V.M.; Mechanisms and functions of inflammasomes. Cell 2014,157(5),1013-1022","journal-title":"Cell"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","volume":"10","author":"Tanaka T.","year":"2018","unstructured":"Tanaka T.; Narazaki M.; Kishimoto T.; Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol 2018,10(8),a028456","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","volume":"64","author":"Schmidt-Arras D.","year":"2016","unstructured":"Schmidt-Arras D.; Rose-John S.; IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016,64(6),1403-1415","journal-title":"J Hepatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2147\/JIR.S302975","volume":"14","author":"Li L.","year":"2021","unstructured":"Li L.; Chen L.; Lin F.; Mu J.; Wang D.; Zhang W.; Mi L.; Qin Y.; Zhou Y.; Study of the expression of inflammatory factors IL-4, IL-6, IL-10, and IL-17 in liver failure complicated by coagulation dysfunction and sepsis. J Inflamm Res 2021,14,1447-1453","journal-title":"J Inflamm Res"},{"key":"ref=39","first-page":"1906","volume":"15","author":"Wang N.","year":"2018","unstructured":"Wang N.; Wang J.; Jiang R.; Effects of IL-10 on OX62, MHC-II and CD86 in bone marrow DCs in rats with organophosphate poisoning. Exp Ther Med 2018,15(2),1906-1909","journal-title":"Exp Ther Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"McGeachy M.J.","year":"2019","unstructured":"McGeachy M.J.; Cua D.J.; Gaffen S.L.; The IL-17 family of cytokines in health and disease. Immunity 2019,50(4),892-906","journal-title":"Immunity"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","volume":"69","author":"Mathurin P.","year":"2018","unstructured":"Mathurin P.; Hadengue A.; Bataller R.; Addolorato G.; Burra P.; Burt A.; EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu2018,69(1),154-181","journal-title":"J Hepatol"},{"key":"ref=42","first-page":"147","volume":"38","author":"Osna N.A.","year":"2017","unstructured":"Osna N.A.; Donohue T.M.; Kharbanda K.K.; Alcoholic liver disease: pathogenesis and current management. Alcohol Res 2017,38(2),147-161","journal-title":"Alcohol Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/nure.12027","volume":"71","author":"Elamin E.E.","year":"2013","unstructured":"Elamin E.E.; Masclee A.A.; Dekker J.; Jonkers D.M.; Ethanol metabolism and its effects on the intestinal epithelial barrier. Nutr Rev 2013,71(7),483-499","journal-title":"Nutr Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1530-0277.2010.01398.x","volume":"35","author":"Szabo G.","year":"2011","unstructured":"Szabo G.; Mandrekar P.; Petrasek J.; Catalano D.; The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol Clin Exp Res 2011,35(5),782-786","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=45","first-page":"547","volume":"119","author":"Hill D.B.","year":"1992","unstructured":"Hill D.B.; Marsano L.; Cohen D.; Allen J.; Shedlofsky S.; McClain C.J.; Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992,119(5),547-552","journal-title":"J Lab Clin Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1053\/j.gastro.2008.01.016","volume":"134","author":"Horiguchi N.","year":"2008","unstructured":"Horiguchi N.; Wang L.; Mukhopadhyay P.; Park O.; Jeong W.I.; Lafdil F.; Osei-Hyiaman D.; Moh A.; Fu X.Y.; Pacher P.; Kunos G.; Gao B.; Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008,134(4),1148-1158","journal-title":"Gastroenterology"},{"key":"ref=47","first-page":"205","volume":"1","author":"El-Assal O.","year":"2004","unstructured":"El-Assal O.; Hong F.; Kim W.H.; Radaeva S.; Gao B.; IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver. Cell Mol Immunol 2004,1(3),205-211","journal-title":"Cell Mol Immunol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1271\/bbb.110061","volume":"75","author":"Xing W.W.","year":"2011","unstructured":"Xing W.W.; Zou M.J.; Liu S.; Xu T.; Wang J.X.; Xu D.G.; Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci Biotechnol Biochem 2011,75(7),1290-1294","journal-title":"Biosci Biotechnol Biochem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1530-0277.2010.01399.x","volume":"35","author":"Miller A.M.","year":"2011","unstructured":"Miller A.M.; Horiguchi N.; Jeong W.I.; Radaeva S.; Gao B.; Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res 2011,35(5),787-793","journal-title":"Alcohol Clin Exp Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/liv.13642","volume":"38","author":"Grabherr F.","year":"2018","unstructured":"Grabherr F.; Grander C.; Adolph T.E.; Wieser V.; Mayr L.; Enrich B.; Macheiner S.; Sangineto M.; Reiter A.; Viveiros A.; Zoller H.; Bufler P.; Moschen A.R.; Dinarello C.A.; Tilg H.; Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease. Liver Int 2018,38(6),1095-1101","journal-title":"Liver Int"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10753-011-9381-x","volume":"35","author":"Ahmadabadi B.N.","year":"2012","unstructured":"Ahmadabadi B.N.; Hassanshahi G.; Arababadi M.K.; Leanza C.; Kennedy D.; The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. Inflammation 2012,35(3),818-821","journal-title":"Inflammation"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1002\/jcp.24967","volume":"230","author":"Luo M.X.M.","year":"2015","unstructured":"Luo M.X.M.; Wong S.H.; Chan M.T.V.; Yu L.; Yu S.S.B.; Wu F.; Xiao Z.; Wang X.; Zhang L.; Cheng A.S.; Ng S.S.; Chan F.K.; Cho C.H.; Yu J.; Sung J.J.; Wu W.K.; Autophagy Mediates HBx-Induced Nuclear Factor-&#x3BA;B Activation and Release of IL-6, IL-8, and CXCL2 in Hepatocytes. J Cell Physiol 2015,230(10),2382-2389","journal-title":"J Cell Physiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.14218\/JCTH.2015.00024","volume":"3","author":"Lan T.","year":"2015","unstructured":"Lan T.; Chang L.; Wu L.; Yuan Y.F.; Il-6 plays a crucial role in hbv infection. J Clin Transl Hepatol 2015,3(4),271-276","journal-title":"J Clin Transl Hepatol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1128\/jvi.71.4.3236-3243.1997","volume":"71","author":"Cavanaugh V.J.","year":"1997","unstructured":"Cavanaugh V.J.; Guidotti L.G.; Chisari F.V.; Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997,71(4),3236-3243","journal-title":"J Virol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajpath.2012.08.043","volume":"182","author":"Cobleigh M.A.","year":"2013","unstructured":"Cobleigh M.A.; Robek M.D.; Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis. Am J Pathol 2013,182(1),21-28","journal-title":"Am J Pathol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1053\/j.gastro.2011.06.051","volume":"141","author":"Zhang Y.","year":"2011","unstructured":"Zhang Y.; Cobleigh M.A.; Lian J.Q.; Huang C.X.; Booth C.J.; Bai X.F.; Robek M.D.; A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011,141(5),1897-1906","journal-title":"Gastroenterology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"e0179605","DOI":"10.1371\/journal.pone.0179605","volume":"12","author":"Cheng S.T.","year":"2017","unstructured":"Cheng S.T.; Tang H.; Ren J.H.; Chen X.; Huang A.L.; Chen J.; Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. PLoS One 2017,12(6),e0179605","journal-title":"PLoS One"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1007\/s10620-020-06077-w","volume":"65","author":"Yang L.","year":"2020","unstructured":"Yang L.; Zhang Q.; Song J.; Wang W.; Jin Z.; Interleukin-35 suppresses CD8 T cell activity in patients with viral hepatitis-induced acute-on-chronic liver failure. Dig Dis Sci 2020,65(12),3614-3623","journal-title":"Dig Dis Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"569575","DOI":"10.3389\/fphar.2020.569575","volume":"11","author":"Hu S.","year":"2021","unstructured":"Hu S.; Lian P.P.; Hu Y.; Zhu X.Y.; Jiang S.W.; Ma Q.; Li L.Y.; Yang J.F.; Yang L.; Guo H.Y.; Zhou H.; Yang C.C.; Meng X.M.; Li J.; Li H.W.; Xu T.; Zhou H.; The Role of IL-35 in the pathophysiological processes of kiver disease. Front Pharmacol 2021,11,569575","journal-title":"Front Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"Chalasani N.","year":"2018","unstructured":"Chalasani N.; Younossi Z.; Lavine J.E.; Charlton M.; Cusi K.; Rinella M.; Harrison S.A.; Brunt E.M.; Sanyal A.J.; The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the american association for the study of liver diseases. Hepatology 2018,67(1),328-357","journal-title":"Hepatology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"Tilg H.","year":"2010","unstructured":"Tilg H.; Moschen A.R.; Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010,52(5),1836-1846","journal-title":"Hepatology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"20704","DOI":"10.3390\/ijms141020704","volume":"14","author":"Takaki A.","year":"2013","unstructured":"Takaki A.; Kawai D.; Yamamoto K.; Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2013,14(10),20704-20728","journal-title":"Int J Mol Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"31S","DOI":"10.1016\/0002-9343(91)90281-2","volume":"91","author":"Sies H.","year":"1991","unstructured":"Sies H.; Oxidative stress: from basic research to clinical application. Am J Med 1991,91(3C),31S-38S","journal-title":"Am J Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3945\/an.116.013151","volume":"8","author":"Mokhtari Z.","year":"2017","unstructured":"Mokhtari Z.; Gibson D.L.; Hekmatdoost A.; Nonalcoholic fatty liver disease, the gut microbiome, and diet. Adv Nutr 2017,8(2),240-252","journal-title":"Adv Nutr"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/hep.26746","volume":"59","author":"Harley I.T.W.","year":"2014","unstructured":"Harley I.T.W.; Stankiewicz T.E.; Giles D.A.; Softic S.; Flick L.M.; Cappelletti M.; Sheridan R.; Xanthakos S.A.; Steinbrecher K.A.; Sartor R.B.; Kohli R.; Karp C.L.; Divanovic S.; IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 2014,59(5),1830-1839","journal-title":"Hepatology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/intimm\/dxq030","volume":"22","author":"Kishimoto T.","year":"2010","unstructured":"Kishimoto T.; IL-6: from its discovery to clinical applications. Int Immunol 2010,22(5),347-352","journal-title":"Int Immunol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.1210\/en.2006-0417","volume":"147","author":"den Boer M.A.M.","year":"2006","unstructured":"den Boer M.A.M.; Voshol P.J.; Schr\u00f6der-van der Elst J.P.; Korsheninnikova E.; Ouwens D.M.; Kuipers F.; Havekes L.M.; Romijn J.A.; Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 2006,147(10),4553-4558","journal-title":"Endocrinology"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jhep.2010.03.004","volume":"53","author":"Yang L.","year":"2010","unstructured":"Yang L.; Zhang Y.; Wang L.; Fan F.; Zhu L.; Li Z.; Ruan X.; Huang H.; Wang Z.; Huang Z.; Huang Y.; Yan X.; Chen Y.; Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010,53(2),339-347","journal-title":"J Hepatol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1159\/000444556","volume":"34","author":"Weiskirchen R.","year":"2016","unstructured":"Weiskirchen R.; Tacke F.; Liver fibrosis: from pathogenesis to novel therapies. Dig Dis 2016,34(4),410-422","journal-title":"Dig Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3389\/fmed.2015.00072","volume":"2","author":"van Dijk F.","year":"2015","unstructured":"van Dijk F.; Olinga P.; Poelstra K.; Beljaars L.; Targeted therapies in liver fibrosis: Combining the best parts of platelet-derived growth factor BB and interferon gamma. Front Med (Lausanne) 2015,2,72","journal-title":"Front Med (Lausanne)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/cphy.c120035","volume":"3","author":"Puche J.E.","year":"2013","unstructured":"Puche J.E.; Saiman Y.; Friedman S.L.; Hepatic stellate cells and liver fibrosis. Compr Physiol 2013,3(4),1473-1492","journal-title":"Compr Physiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"G1324","DOI":"10.1152\/ajpgi.90564.2008","volume":"296","author":"Gieling R.G.","year":"2009","unstructured":"Gieling R.G.; Wallace K.; Han Y.P.; Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009,296(6),G1324-G1331","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3748\/wjg.v21.i5.1531","volume":"21","author":"Lu D.H.","year":"2015","unstructured":"Lu D.H.; Guo X.Y.; Qin S.Y.; Luo W.; Huang X.L.; Chen M.; Wang J.X.; Ma S.J.; Yang X.W.; Jiang H.X.; Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines. World J Gastroenterol 2015,21(5),1531-1545","journal-title":"World J Gastroenterol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1084\/jem.20092054","volume":"207","author":"Sonnenberg G.F.","year":"2010","unstructured":"Sonnenberg G.F.; Nair M.G.; Kirn T.J.; Zaph C.; Fouser L.A.; Artis D.; Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010,207(6),1293-1305","journal-title":"J Exp Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3892\/mmr.2014.2681","volume":"11","author":"Shi M.","year":"2015","unstructured":"Shi M.; Wei J.; Dong J.; Meng W.; Ma J.; Wang T.; Wang N.; Wang Y.; Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis. Mol Med Rep 2015,11(1),121-126","journal-title":"Mol Med Rep"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"103213","DOI":"10.1016\/j.ebiom.2021.103213","volume":"64","author":"Wang H.H.","year":"2021","unstructured":"Wang H.H.; Huang J.H.; Sue M.H.; Ho W.C.; Hsu Y.H.; Chang K.C.; Chang M.S.; Interleukin-24 protects against liver injury in mouse models. EBio Med 2021,64,103213","journal-title":"EBio Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"603649","DOI":"10.3389\/fimmu.2021.603649","volume":"12","author":"Mountford S.","year":"2021","unstructured":"Mountford S.; Effenberger M.; Noll-Puchta H.; Griessmair L.; Ringleb A.; Haas S.; Denk G.; Reiter F.P.; Mayr D.; Dinarello C.A.; Tilg H.; Bufler P.; Modulation of liver inflammation and fibrosis by interleukin-37. Front Immunol 2021,12,603649","journal-title":"Front Immunol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/hep.31031","volume":"72","author":"Hwang S.","year":"2020","unstructured":"Hwang S.; He Y.; Xiang X.; Seo W.; Kim S.J.; Ma J.; Ren T.; Park S.H.; Zhou Z.; Feng D.; Kunos G.; Gao B.; Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology 2020,72(2),412-429","journal-title":"Hepatology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ejso.2006.10.036","volume":"33","author":"Hsia C.Y.","year":"2007","unstructured":"Hsia C.Y.; Huo T.I.; Chiang S.Y.; Lu M.F.; Sun C.L.; Wu J.C.; Lee P.C.; Chi C.W.; Lui W.Y.; Lee S.D.; Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007,33(2),208-212","journal-title":"Eur J Surg Oncol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","volume":"33","author":"Dudakov J.A.","year":"2015","unstructured":"Dudakov J.A.; Hanash A.M.; van den Brink M.R.M.; Interleukin-22: immunobiology and pathology. Annu Rev Immunol 2015,33,747-785","journal-title":"Annu Rev Immunol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/hep.26528","volume":"59","author":"Waidmann O.","year":"2014","unstructured":"Waidmann O.; Kronenberger B.; Scheiermann P.; K\u00f6berle V.; M\u00fchl H.; Piiper A.; Interleukin-22 serum levels are a negative prognostic indicator in patients with hepatocellular carcinoma. Hepatology 2014,59(3),1207","journal-title":"Hepatology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.jss.2010.04.004","volume":"163","author":"Roth G.A.","year":"2010","unstructured":"Roth G.A.; Zimmermann M.; Lubsczyk B.A.; Pilz J.; Faybik P.; Hetz H.; Hacker S.; Mangold A.; Bacher A.; Krenn C.G.; Ankersmit H.J.; Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J Surg Res 2010,163(2),e79-e83","journal-title":"J Surg Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.4049\/jimmunol.1800627","volume":"201","author":"Jin Z.","year":"2018","unstructured":"Jin Z.; Lei L.; Lin D.; Liu Y.; Song Y.; Gong H.; Zhu Y.; Mei Y.; Hu B.; Wu Y.; Zhang G.; Liu H.; IL-33 released in the liver inhibits tumor growth via promotion of cd4 and cd8 t cell responses in hepatocellular carcinoma. J Immunol 2018,201(12),3770-3779","journal-title":"J Immunol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-18-3531","volume":"26","author":"Tsai C.L.","year":"2020","unstructured":"Tsai C.L.; Chang J.S.; Yu M.C.; Lee C.H.; Chen T.C.; Chuang W.Y.; Kuo W.L.; Lin C.C.; Lin S.M.; Hsieh S.Y.; Functional genomics identifies hepatitis-induced STAT3-TyrO3-STAT3 signaling as a potential therapeutic target of hepatoma. Clin Cancer Res 2020,26(5),1185-1197","journal-title":"Clin Cancer Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000315247","volume":"78","author":"Yeh S.H.","year":"2010","unstructured":"Yeh S.H.; Chen P.J.; Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010,78(Suppl. 1),172-179","journal-title":"Oncology"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/hep.510310123","volume":"31","author":"Kovalovich K.","year":"2000","unstructured":"Kovalovich K.; DeAngelis R.A.; Li W.; Furth E.E.; Ciliberto G.; Taub R.; Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 2000,31(1),149-159","journal-title":"Hepatology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/hep.510280621","volume":"28","author":"Louis H.","year":"1998","unstructured":"Louis H.; Van Laethem J.L.; Wu W.; Quertinmont E.; Degraef C.; Van den Berg K.; Demols A.; Goldman M.; Le Moine O.; Geerts A.; Devi\u00e8re J.; Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998,28(6),1607-1615","journal-title":"Hepatology"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","volume":"166","author":"Tang Y.","year":"2011","unstructured":"Tang Y.; Bian Z.; Zhao L.; Liu Y.; Liang S.; Wang Q.; Han X.; Peng Y.; Chen X.; Shen L.; Qiu D.; Li Z.; Ma X.; Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011,166(2),281-290","journal-title":"Clin Exp Immunol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","volume":"143","author":"Meng F.","year":"2012","unstructured":"Meng F.; Wang K.; Aoyama T.; Grivennikov S.I.; Paik Y.; Scholten D.; Cong M.; Iwaisako K.; Liu X.; Zhang M.; \u00d6sterreicher C.H.; Stickel F.; Ley K.; Brenner D.A.; Kisseleva T.; Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012,143(3),765-776.e3","journal-title":"Gastroenterology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/hep.25744","volume":"56","author":"Kong X.","year":"2012","unstructured":"Kong X.; Feng D.; Wang H.; Hong F.; Bertola A.; Wang F.S.; Gao B.; Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012,56(3),1150-1159","journal-title":"Hepatology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/hep.24486","volume":"54","author":"Jiang R.","year":"2011","unstructured":"Jiang R.; Tan Z.; Deng L.; Chen Y.; Xia Y.; Gao Y.; Wang X.; Sun B.; Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011,54(3),900-909","journal-title":"Hepatology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1111\/j.1582-4934.2009.00801.x","volume":"14","author":"Marvie P.","year":"2010","unstructured":"Marvie P.; Lisbonne M.; L\u2019helgoualc\u2019h A.; Rauch M.; Turlin B.; Preisser L.; Bourd-Boittin K.; Th\u00e9ret N.; Gascan H.; Piquet-Pellorce C.; Samson M.; Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010,14(6B),1726-1739","journal-title":"J Cell Mol Med"},{"key":"ref=93","year":"2013","unstructured":"Genetic polymorphisms of interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma. ClinicalTrialsgov Available from:  (Accessed June 2021).2013","journal-title":"ClinicalTrialsgov"},{"key":"ref=94","year":"2021","unstructured":"IL-1 Signal Inhibition in Alcoholic Hepatitis. ClinicalTrialsgov Available from:  (Accessed October 2021).2021","journal-title":"ClinicalTrialsgov"},{"key":"ref=95","year":"2018","unstructured":"Combination Therapy with Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients. ClinicalTrialsgov Available from:  (Accessed 24 June 2021).2018","journal-title":"ClinicalTrialsgov"},{"key":"ref=96","year":"2021","unstructured":"Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients. ClinicalTrialsgov Available from:  (Accessed October 2021).2021","journal-title":"ClinicalTrialsgov"},{"key":"ref=97","year":"2011","unstructured":"Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery. ClinicalTrialsgov Available from:  (Accessed October 2021).2011","journal-title":"ClinicalTrialsgov"},{"key":"ref=98","year":"2021","unstructured":"Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera. ClinicalTrialsgov Available from:  (Accessed October 2021).2021","journal-title":"ClinicalTrialsgov"},{"key":"ref=99","year":"2012","unstructured":"Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone. ClinicalTrialsgov Available from:  (Accessed October 2021).2012","journal-title":"ClinicalTrialsgov"},{"key":"ref=100","year":"2013","unstructured":"Interleukin 12 and Trastuzumab in Treating Patients with Cancer That Has High Level Of HER2\/Neu. ClinicalTrialsgov Available from:  (Accessed 24 June 2021).2013","journal-title":"ClinicalTrialsgov"},{"key":"ref=101","year":"2021","unstructured":"A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-Alcoholic Fatty Liver Disease (NAFLD). ClinicalTrialsgov Available from:  (Accessed 24 June 2021).2021","journal-title":"ClinicalTrialsgov"},{"key":"ref=102","year":"2014","unstructured":"Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28B. ClinicalTrialsgov Available from:  (Accessed October 2021).2014","journal-title":"ClinicalTrialsgov"},{"key":"ref=103","year":"2015","unstructured":"ClinicalTrials.gov. A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Na\u00efve and Treatment-Experienced Patients With Chronic Hepatitis C. ClinicalTrialsgov Available from:  (Accessed October 2021).2015","journal-title":"ClinicalTrialsgov"},{"key":"ref=104","year":"2017","unstructured":"ClinicalTrials.gov. A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a). ClinicalTrialsgov Available from:  (Accessed October 2021).2017","journal-title":"ClinicalTrialsgov"},{"key":"ref=105","year":"2019","unstructured":"IL-35+Breg\/IL-35 Effect on T cell Immune in Patients with CHB. ClinicalTrialsgov Available from:  (Accessed 24 June 2021).2019","journal-title":"ClinicalTrialsgov"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530321666211124102837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/198259\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530321666211124102837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T21:40:04Z","timestamp":1659390004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/198259\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530321666211124102837","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}